PT - JOURNAL ARTICLE AU - Philippe Halfon AU - Eloïne Bestion AU - Keivan Zandi AU - Julien Andreani AU - Jean-Pierre Baudoin AU - Bernard La Scola AU - Jean-Louis Mege AU - Soraya Mezouar AU - Raymond F. Schinazi TI - GNS561 exhibits potent <em>in vitro</em> antiviral activity against SARS-CoV-2 through autophagy inhibition AID - 10.1101/2020.10.06.327635 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.10.06.327635 4099 - http://biorxiv.org/content/early/2020/10/06/2020.10.06.327635.short 4100 - http://biorxiv.org/content/early/2020/10/06/2020.10.06.327635.full AB - Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) has spread quickly worldwide, with more than 29 million cases and 920,000 deaths. Interestingly, coronaviruses were found to subvert and hijack the autophagic process to allow their viral replication. One of the spotlights had been focused on the autophagy inhibitors as a target mechanism effective in the inhibition of SARS-CoV-2 infection. Consequently, chloroquine (CQ) and hydroxychloroquine (HCQ), a derivative of CQ, was suggested as the first potentially be therapeutic strategies as they are known to be autophagy inhibitors. Then, they were used as therapeutics in SARS-CoV-2 infection along with remdesivir, for which the FDA approved emergency use authorization. Here, we investigated the antiviral activity and associated mechanism of GNS561, a small basic lipophilic molecule inhibitor of late-stage autophagy, against SARS-CoV-2. Our data indicated that GNS561 showed the highest antiviral effect for two SARS-CoV-2 strains compared to CQ and remdesivir. Focusing on the autophagy mechanism, we showed that GNS561, located in LAMP2-positive lysosomes, together with SARS-CoV-2, blocked autophagy by increasing the size of LC3-II spots and the accumulation of autophagic vacuoles in the cytoplasm with the presence of multilamellar bodies characteristic of a complexed autophagy. Finally, our study revealed that the combination of GNS561 and remdesivir was associated with a strong synergistic antiviral effect against SARS-CoV-2. Overall, our study highlights GNS561 as a powerful drug in SARS-CoV-2 infection and supports that the hypothesis that autophagy inhibitors could be an alternative strategy for SARS-CoV-2 infection.Competing Interest StatementP.H., E.B. and S.M. are Genoscience Pharma Employees.